Supplementary References

1.
Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D.C., White, J.R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., et al. (2020). Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer 1, 99–111. 10.1038/s43018-019-0008-8.

"Somatic mutations, consisting of point mutations, insertions, and deletions across the whole exome were identified using the VariantDx custom software for identifying mutations in matched tumor and normal samples as previously described13,44. Somatic sequence alteration calls for cohort 1* are listed in Supplementary Table 3"

Supplementary Table 3: https://static-content.springer.com/esm/art%3A10.1038%2Fs43018-019-0008-8/MediaObjects/43018_2019_8_MOESM2_ESM.xlsx

*"we performed genome-wide sequence and structural analyses for a cohort of 104 NSCLC patients treated with ICB (cohort 1; Supplementary Table 1 and Methods)."

HINT: No IFITM mutations

2.
Anagnostou, V., Bruhm, D.C., Niknafs, N., White, J.R., Shao, X.M., Sidhom, J.W., Stein, J., Tsai, H.-L., Wang, H., Belcaid, Z., et al. (2020). Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Rep Med 1, 100139. 10.1016/j.xcrm.2020.100139.

"Somatic mutations, consisting of point mutations, insertions, and deletions across the whole exome were identified using the VariantDx custom software for identifying mutations in matched tumor and normal samples* as previously described (Personal Genome Diagnostics, Baltimore, MD)10,47. Somatic sequence alterations are listed in Table S1B.

Table S1B: https://ars.els-cdn.com/content/image/1-s2.0-S266637912030183X-mmc2.xlsx

*"comprehensive genomic and transcriptomic tumor analyses in conjunction with T cell repertoire analyses for 64 melanoma patients treated with immune checkpoint blockade as part of the CheckMate-038 clinical trial (NCT01621490; Figure S1; Table S1A) ... To explore the genomic landscape of these tumors, we performed whole-exome sequencing (WES) of matched tumor-normal pairs"

3.
Braun, D.A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A.C., Jegede, O.A., Elagina, L., et al. (2020). Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 1–10. 10.1038/s41591-020-0839-y.

"WES data were available from 454 patients (261 patients treated with anti-PD-1 and 193 patients treated with mTOR inhibition; Supplementary Table 2)"

Supplementary Table 2: https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-020-0839-y/MediaObjects/41591_2020_839_MOESM2_ESM.xlsx

4.
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X.Q., Lu, H., Nebozhyn, M., et al. (2018). Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362. 10.1126/science.aar3593.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

[Note from Song et al: 
"As  the  genomic  and  clinical response  information  were  not  provided  in  the  supplementary  tables,  best  objective  response information, TMB, and alteration status of JAK1 and JAK2 were instead obtained from Litchfield et al."

Comment:
I am unable to find this data in the Litchfield paper either!]

5.
Litchfield, K., Reading, J.L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T.B.K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021). Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596-614.e14. 10.1016/j.cell.2021.01.002.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

6.
Frigola, J., Navarro, A., Carbonell, C., Callejo, A., Iranzo, P., Cedrés, S., Martinez-Marti, A., Pardo, N., Saoudi-Gonzalez, N., Martinez, D., et al. (2021). Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol 15, 887–900. 10.1002/1878-0261.12891.

"We assembled a cohort of 47 patients with NSCLC receiving ICIs that was enriched in long‐term responders [>18 months of progression‐free survival (PFS)]. We performed whole‐exome sequencing from tumor samples"

Table S2. Patient information and clinical outcome: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024716/bin/MOL2-15-887-s007.txt
Table S4. Mutations per patient: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024716/bin/MOL2-15-887-s004.txt

7.
Hellmann, M.D., Nathanson, T., Rizvi, H., Creelan, B.C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J.B., Mangarin, L.M.B., Abu-Akeel, M., et al. (2018). Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33, 843-852.e4. 10.1016/j.ccell.2018.03.018.

"We performed whole-exome sequencing (WES) on tumor tissue and paired blood collected from 75 patients with NSCLC treated with nivolumab plus ipilimumab as part of the CheckMate-012 study"

Table S2. Clinical Characteristics, Outcomes, and Summary Molecular Features of Individual Patients: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953836/bin/mmc2.xlsx
Table S3. Genomic Characteristics: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953836/bin/mmc3.xlsx

8.
Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1. 10.1126/scisignal.2004088.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

9.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov 2, 401–404. 10.1158/2159-8290.CD-12-0095.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

10.
Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016). Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165, 35–44. 10.1016/j.cell.2016.02.065.

"We analyzed the whole exome sequences (WES) of 38 pretreatment (pembrolizumab, nivolumab) melanoma tumors (responding, n=21; non-responding, n=17; total 34 of 38 pretreatment; 4 of 38 early on-treatment; 14 of 38 patients with prior MAPKi treatment; Table S1A) and patient-matched normal tissues for germline references. Responding pretreatment tumors were derived from patients who went on to have complete or partial responses or stable disease control (with mixed responses excluded) in response to anti-PD-1 therapy"

Table S1D: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808437/bin/NIHMS765463-supplement-5.xlsx

11.
Jung, H., Kim, H.S., Kim, J.Y., Sun, J.-M., Ahn, J.S., Ahn, M.-J., Park, K., Esteller, M., Lee, S.-H., and Choi, J.K. (2019). DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun 10, 4278. 10.1038/s41467-019-12159-9.

"A total of 60 advanced non-small cell lung carcinoma patients who were treated with anti-PD-1/PD-L1 from 2014 to 2017 at Samsung Medical Center were enrolled for this study"

Supplementary Data 5: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753140/bin/41467_2019_12159_MOESM8_ESM.xlsx

NO OUTCOME DATA

12.
Kim, S.T., Cristescu, R., Bass, A.J., Kim, K.-M., Odegaard, J.I., Kim, K., Liu, X.Q., Sher, X., Jung, H., Lee, M., et al. (2018). Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24, 1449–1458. 10.1038/s41591-018-0101-z.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

13.Bareche, Y., Kelly, D., Abbas-Aghababazadeh, F., Nakano, M., Esfahani, P.N., Tkachuk, D., Mohammad, H., Samstein, R., Lee, C.-H., Morris, L.G.T., et al. (2022). Leveraging Big Data of Immune Checkpoint Blockade Response Identifies Novel Potential Targets. Annals of Oncology 0. 10.1016/j.annonc.2022.08.084.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

14.
Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372, 2509–2520. 10.1056/NEJMoa1500596.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

15.
Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019). Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med 25, 1916–1927. 10.1038/s41591-019-0654-5.

"we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors"

Supplementary Data 1. Gene-level mutation calls; copy number alterations; immune cell signatures; mutational signatures; and ssGSEA signatures using Hallmarks gene sets: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898788/bin/41591_2019_654_MOESM2_ESM.xlsx
Supplementary Tables 1–9 (Outcomes): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898788/bin/41591_2019_654_MOESM4_ESM.xlsx

16.
Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel, E.E., Koeppen, H., Astarita, J.L., Cubas, R., et al. (2018). TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548. 10.1038/nature25501.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

17.
McDermott, D.F., Huseni, M.A., Atkins, M.B., Motzer, R.J., Rini, B.I., Escudier, B., Fong, L., Joseph, R.W., Pal, S.K., Reeves, J.A., et al. (2018). Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 24, 749–757. 10.1038/s41591-018-0053-3.

NO TUMOR/MUTATION LEVEL SUPPLEMENTARY TABLES

18.
Miao, D., Margolis, C.A., Vokes, N.I., Liu, D., Taylor-Weiner, A., Wankowicz, S.M., Adeegbe, D., Keliher, D., Schilling, B., Tracy, A., et al. (2018). Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 50, 1271–1281. 10.1038/s41588-018-0200-2.

19.
Miao, D., Margolis, C.A., Gao, W., Voss, M.H., Li, W., Martini, D.J., Norton, C., Bossé, D., Wankowicz, S.M., Cullen, D., et al. (2018). Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 10.1126/science.aan5951.

20.
Nathanson, T., Ahuja, A., Rubinsteyn, A., Aksoy, B.A., Hellmann, M.D., Miao, D., Van Allen, E., Merghoub, T., Wolchok, J.D., Snyder, A., et al. (2017). Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunol Res 5, 84–91. 10.1158/2326-6066.CIR-16-0019.

21.
Pleasance, E., Titmuss, E., Williamson, L., Kwan, H., Culibrk, L., Zhao, E.Y., Dixon, K., Fan, K., Bowlby, R., Jones, M.R., et al. (2020). Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nat Cancer 1, 452–468. 10.1038/s43018-020-0050-6.

22.
Riaz, N., Havel, J.J., Makarov, V., Desrichard, A., Urba, W.J., Sims, J.S., Hodi, F.S., Martín-Algarra, S., Mandal, R., Sharfman, W.H., et al. (2017). Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 171, 934-949.e16. 10.1016/j.cell.2017.09.028.

23.Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128. 10.1126/science.aaa1348.

24.
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J.L., Rekhtman, N., et al. (2018). Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol 36, 633–641. 10.1200/JCO.2017.75.3384.

25.
Roh, W., Chen, P.-L., Reuben, A., Spencer, C.N., Prieto, P.A., Miller, J.P., Gopalakrishnan, V., Wang, F., Cooper, Z.A., Reddy, S.M., et al. (2017). Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine 9, eaah3560. 10.1126/scitranslmed.aah3560.

26.
Sade-Feldman, M., Jiao, Y.J., Chen, J.H., Rooney, M.S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S.L., Hammond, M.R., Vitzthum, H., Blackmon, S.M., et al. (2017). Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun 8, 1–11. 10.1038/s41467-017-01062-w.

27.
Shim, J.H., Kim, H.S., Cha, H., Kim, S., Kim, T.M., Anagnostou, V., Choi, Y.-L., Jung, H.A., Sun, J.-M., Ahn, J.S., et al. (2020). HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Annals of Oncology 31, 902–911. 10.1016/j.annonc.2020.04.004.

28.Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. (2014). Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine 371, 2189–2199. 10.1056/NEJMoa1406498.

29.
Snyder, A., Nathanson, T., Funt, S.A., Ahuja, A., Novik, J.B., Hellmann, M.D., Chang, E., Aksoy, B.A., Al-Ahmadie, H., Yusko, E., et al. (2017). Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLOS Medicine 14, e1002309. 10.1371/journal.pmed.1002309.

30.
Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Foppen, M.H.G., Goldinger, S.M., et al. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211. 10.1126/science.aad0095.

31.
Cindy Yang, S.Y., Lien, S.C., Wang, B.X., Clouthier, D.L., Hanna, Y., Cirlan, I., Zhu, K., Bruce, J.P., El Ghamrasni, S., Iafolla, M.A.J., et al. (2021). Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Commun 12, 5137. 10.1038/s41467-021-25432-7.

32.
Brandes, N., Goldman, G., Wang, C.H., Ye, C.J., and Ntranos, V. (2022). Genome-wide prediction of disease variants with a deep protein language model. 2022.08.25.505311. 10.1101/2022.08.25.505311.

33.Frazer, J., Notin, P., Dias, M., Gomez, A., Min, J.K., Brock, K., Gal, Y., and Marks, D.S. (2021). Disease variant prediction with deep generative models of evolutionary data. Nature 599, 91–95. 10.1038/s41586-021-04043-8.

34.
Dubrot, J., Lane-Reticker, S.K., Kessler, E.A., Ayer, A., Mishra, G., Wolfe, C.H., Zimmer, M.D., Du, P.P., Mahapatra, A., Ockerman, K.M., et al. (2021). In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity 54, 571-585.e6. 10.1016/j.immuni.2021.01.001.

35.
Freeman, A.J., Vervoort, S.J., Ramsbottom, K.M., Kelly, M.J., Michie, J., Pijpers, L., Johnstone, R.W., Kearney, C.J., and Oliaro, J. (2019). Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. Cell Rep 28, 2784-2794.e5. 10.1016/j.celrep.2019.08.017.

36.
Kearney, C.J., Vervoort, S.J., Hogg, S.J., Ramsbottom, K.M., Freeman, A.J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K.K., Knight, D.A., et al. (2018). Tumor immune evasion arises through loss of TNF sensitivity. Science Immunology 3, eaar3451. 10.1126/sciimmunol.aar3451.

37.
Lawson, K.A., Sousa, C.M., Zhang, X., Kim, E., Akthar, R., Caumanns, J.J., Yao, Y., Mikolajewicz, N., Ross, C., Brown, K.R., et al. (2020). Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature 586, 120–126. 10.1038/s41586-020-2746-2.

38.
Larson, R.C., Kann, M.C., Bailey, S.R., Haradhvala, N.J., Llopis, P.M., Bouffard, A.A., Scarfó, I., Leick, M.B., Grauwet, K., Berger, T.R., et al. (2022). CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature 604, 563–570. 10.1038/s41586-022-04585-5.

39.
Li, F., Huang, Q., Luster, T.A., Hu, H., Zhang, H., Ng, W.-L., Khodadadi-Jamayran, A., Wang, W., Chen, T., Deng, J., et al. (2020). In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma. Cancer Discovery 10, 270–287. 10.1158/2159-8290.CD-19-0780.

40.
Manguso, R.T., Pope, H.W., Zimmer, M.D., Brown, F.D., Yates, K.B., Miller, B.C., Collins, N.B., Bi, K., LaFleur, M.W., Juneja, V.R., et al. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413–418. 10.1038/nature23270.

41.
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R.E., Luoma, A.M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018). A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing. Science 359, 770–775. 10.1126/science.aao1710.

42.
Patel, S.J., Sanjana, N.E., Kishton, R.J., Eidizadeh, A., Vodnala, S.K., Cam, M., Gartner, J.J., Jia, L., Steinberg, S.M., Yamamoto, T.N., et al. (2017). Identification of essential genes for cancer immunotherapy. Nature 548, 537–542. 10.1038/nature23477.

43.
Pech, M.F., Fong, L.E., Villalta, J.E., Chan, L.J., Kharbanda, S., O’Brien, J.J., McAllister, F.E., Firestone, A.J., Jan, C.H., and Settleman, J. (2019). Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. eLife 8, e47362. 10.7554/eLife.47362.

44.
Wang, X., Tokheim, C., Gu, S.S., Wang, B., Tang, Q., Li, Y., Traugh, N., Zeng, Z., Zhang, Y., Li, Z., et al. (2021). In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell 184, 5357-5374.e22. 10.1016/j.cell.2021.09.006.

